Special Issue

Breast Cancer: Molecular Mechanisms, Diagnosis Techniques and Therapeutic Targets

Message from the Guest Editor

Breast cancer remains one of the most common cancers affecting women. Its molecular mechanism involves the growth, migration and invasion of cancerous cells due to dysfunctional proteins and pathways at a genetic level. The main subtypes include Luminal A, Luminal B, HER2-enriched and triple-negative breast cancers. Each has different biomarkers and therapeutic responses. Diagnosis techniques include self-examination, mammography, ultrasound, biopsy and genetic testing. These methods help to identify the stage, type and spread of the cancer. The advancements in molecular biology have led to the formation of therapeutic targets such as hormone receptors (estrogen and progesterone receptors), HER2 proteins and BRCA1 and BRCA2 genes. Targeted therapies based on these receptors and genes have shown better results in treatment. Hormone therapy, radiation therapy, chemotherapy, immunotherapy and surgery are some standard treatment options. This Special Issue aims to present a collection of original research articles and reviews that address the use of modern molecular diagnosis techniques and targeted therapies in breast cancer.

Guest Editor

Dr. Shipra Gandhi

Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Deadline for manuscript submissions

closed (25 March 2025)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/180321

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

MDPI